“RIPping” off Pancreas Cancer's Blockage of Immune Surveillance

MHC-I downregulation is correlated with immunotherapy resistance in PDAC, but efficient strategies to increase cell-surface MHC-I are still lacking. This study by Sang, Zhou, Chen, Yu, and colleagues identified inhibition of tumor-intrinsic RIPK2 as a pharmacologic target to block the degradation of MHC-I on tumor cells and improved PDAC responses to anti–PD-1 immunotherapy.

See related article by Sang et al., p. 326 (1).